Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (25 June 2017)

The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month while New Zealand applicants have two or three a month.

Australian applications

Here are the 192 PCT patent applications relevant to Australia's Life Sciences sector that have published since 22 June 2017, for a publication rate of 3.6 applications per week:

WO/2018/107246, Improving selective internal radiation therapy, Australian National University, 21 June 2018
WO/2018/107244, Composition and uses thereof, Progen PG500 Series Pty Ltd, 21 June 2018
WO/2018/107241, Treatment of iron disorders, University of Sydney, 21 June 2018
WO/2018/107236, Novel compounds as anti-mycobacterials, University of Sydney, 21 June 2018
WO/2018/107228, Reagents for treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and use thereof, Benitec Biopharma, 21 June 2018
WO/2018/107226, Methods of treating ocular disorders, Beta Therapeutics Pty Ltd, 21 June 2018
WO/2018/107216, Non-peptide oxytocin receptor agonists, University of Sydney, 21 June 2018
WO/2018/107205, Radiolabelled material for targeted administration, Australian National University, 21 June 2018
WO/2018/107201, Heparanase inhibitors and use thereof, Beta Therapeutics Pty Ltd, 21 June 2018
WO/2018/107200, Heparanase inhibitors and use thereof, Beta Therapeutics Pty Ltd, 21 June 2018
WO/2018/102890, Visualization constructs, University of Queensland, 14 June 2018
WO/2018/102889, Glycopeptide antibiotic constructs, University of Queensland, 14 June 2018
WO/2018/102885, Modulators of nicotinic acetylcholine receptors and uses thereof, Bionomics, 14 June 2018
WO/2018/102857, Determining cancer responsiveness to treatment, Queensland University of Technology, 14 June 2018
WO/2018/102854, Treatment of obesity and eating disorders, St Vincent's Hospital Sydney, 14 June 2018
WO/2018/102849, Photodynamic therapeutic compounds and photodynamic methods of treatment, Salt and Light Pharmaceuticals Pty Ltd, 14 June 2018
WO/2018/098534, Methods of treating cancer and reagents thereof, Garvan Institute of Medical Research, 7 June 2018
WO/2018/098519, Arsenic compositions, Eupharma Pty Ltd, 7 June 2018
WO/2018/094470, Method and agents for reducing general anaesthetic induced neuroexcitation, University of Queensland, 31 May 2018
WO/2018/094460, Anti-CD300f antibody and uses thereof, Dendrocyte Biotech Pty Ltd, 31 May 2018
WO/2018/091967, Compositions for the treatment of hypertension, George Institute for Global Health, 24 May 2018
WO/2018/090100, Methods and products for reducing resistance to anti-parasitic agents, Resurrect Refugia Pty Ltd, 24 May 2018
WO/2018/090096, Taste masking product, University of Western Australia, 24 May 2018
WO/2018/090073, Nanospheres for cosmetic and pharmaceutical use, Ultraceuticals Pty Ltd, 24 May 2018
WO/2018/089912, Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease, Amgen with five inventors including Stephen Nicholls, 17 May 2018
WO/2018/085890, Reconstituted High Density Lipoprotein treatment of myocardial infarction, CSL Ltd, 17 May 2018
WO/2018/085888, Subtilase Cytotoxin B subunit mutant, Griffith University and University of Adelaide, 17 May 2018
WO/2018/085886, Livestock supplement and use thereof, Charles Sturt University, 17 May 2018
WO/2018/085877, A method of treatment, University of Melbourne, 17 May 2018
WO/2018/085171, Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors, Merck & Co. and ten inventors including Andrew Harvey, 11 May 2018
WO/2018/085170, Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors, Merck & Co. and six inventors including Andrew Harvey, 11 May 2018
WO/2018/081878, Modulation of protein accumulation and uses therefor, Macquarie University, 11 May 2018
WO/2018/081869, Antimicrobial compounds, University of New South Wales, 11 May 2018
WO/2018/081863, 6-substituted derivatives of hexamethylene amiloride as inhibitors of uPA and uses thereof, University of Wollongong, 11 May 2018
WO/2018/081862, Modified antibacterial compositions and methods, University of Melbourne, 11 May 2018
WO/2018/081861, Antimicrobial composition combinations comprising star shaped peptide polymers, University of Melbourne, 11 May 2018
WO/2018/081860, Formulations for radiotherapy and diagnostic imaging, Clarity Pharmaceuticals Pty Ltd, 11 May 2018
WO/2018/081858, Improved analogues of Desferrioxamine B and their uses, University of Sydney, 11 May 2018
WO/2018/081845, Antibacterial compositions and methods, University of Melbourne, 11 May 2018
WO/2018/076074, Mucosal active agent delivery, SUDA Pharmaceuticals, 3 May 2018
WO/2018/076060, Improved generation of muscle lineage cells and therapeutic uses thereof, Genea Biocells, 3 May 2018
WO/2018/076049, Immunogenic protein and method of use, University of Queensland, 3 May 2018
WO/2018/071988, Oral medication formulations, Grunbiotics Pty Ltd, 26 April 2018
WO/2018/071975, Cell population seeding in dermal matrices for endocrine disorder management, Beta Cell Technologies Pty Ltd, 26 April 2018
WO/2018/071967, Cell associated scaffolds for delivery of agents, Australian Foundation for Diabetes Research, 26 April 2018
WO/2018/071959, Cytotoxic particles, Biosceptre, 26 April 2018
WO/2018/068090, Therapeutic agents and methods of producing same, Glycan Biosciences (US) with Deirdre Coombe of Curtin University, 19 April 2018
WO/2018/065923, Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same, EnGeneIC, 12 April 2018
WO/2018/064718, Peptide libraries and methods of use, Queensland Institute of Medical Research, 12 April 2018
WO/2018/064498, Methods of treating epilepsy and related neurological conditions, Pairnomix, LLC (USA) with eight inventors including Steven Petrou, 5 April 2018
WO/2018/058199, Dental caries status disclosing solutions, R.M Creighton Dental Pty Ltd, 5 April 2018
WO/2018/058177, Assembled glycoproteins, Macfarlane Burnet Institute for Medical Research and Public Health, 5 April 2018
WO/2018/053601, Method for preparing a lipid bubble, University of Queensland, 29 March 2018
WO/2018/053597, Coagulation factor binding proteins and uses thereof, CSL Ltd, 29 March 2018
WO/2018/053595, Methods for improving cerebrovascular function and cognition in peri- and post-menopausal women, University of Newcastle, 29 March 2018
WO/2018/053588, Compositions for the treatment of hypertension and/or fibrosis, Vectus Biosystems, 29 March 2018
WO/2018/053587, Compositions for the treatment of hypertension and/or fibrosis, Vectus Biosystems, 29 March 2018
WO/2018/053578, Isotopic compositions, Ambrosis Kambouris, 29 March 2018
WO/2018/049474, Antibody and checkpoint inhibitor combination therapy, Bionomics, 22 March 2018
WO/2018/049471, Reagents for producing T-cells with non-functional T-cell receptors (TCRs) compositions comprising same and use thereof, Benitec Biopharma, 22 March 2018
WO/2018/049468, A method of purifying metal oxide particles and uses thereof, RMIT University, 22 March 2018
WO/2018/049459, Vaccine comprising drug and parasite administration, Griffith University, 22 March 2018
WO/2018/049165, Immunotherapy for polyomaviruses, Atara Biotherapeutics (US) and QIMR Berghofer Medical Research Institute, 15 March 2018
WO/2018/047157, Wound covering with haemostatic action and the method of its creation, Alexander Plotkin (Israel) and Dmitri Menglet, 15 March 2018
WO/2018/045424, Medicinal use of serrulatane diterpenes, University of Sydney, 15 March 2018
WO/2018/045422, Lysine specific histone demethylase-1 inhibitors and uses therefor, University of Canberra, 15 March 2018
WO/2018/045417, A clinical management protocol, Graeme Southwick, 15 March 2018
WO/2018/039748, Wound healing peptide, James Cook University, 8 March 2018
WO/2018/032057, Viral vaccines, Sementis, 22 February 2018
WO/2018/027278, Omega-3 compositions and methods relating thereto, Pharmako Biotechnologies Pty Ltd, 15 February 2018
WO/2018/027274, Metabolites for treatment and prevention of autoimmune disease, Monash University, 15 February 2018
WO/2018/027252, Immune-modulating compounds, QIMR Berghofer Medical Research Institute, 15 February 2018
WO/2018/023170, A method of treatment, Hudson Institute of Medical Research, 8 February 2018
WO/2018/023166, Cannabis composition, Zelda Therapeutics, 8 February 2018
WO/2018/023164, Cannabis composition, Zelda Therapeutics, 8 February 2018
WO/2018/023163, Cannabis composition, Zelda Therapeutics, 8 February 2018
WO/2018/023151, Composition comprising Duddingtonia flagrans, International Animal Health Products Pty Ltd, 8 February 2018
WO/2018/018097, Method of treatment, QBiotics, 1 February 2018
WO/2018/018091, Compositions for the treatment of pulmonary fibrosis, Vectus Biosystems, 1 February 2018
WO/2018/018082, Immunostimulatory compositions and uses therefor, Australian National University, 1 February 2018
WO/2018/018077, Methods of treating breast cancer and reagents therefor, Garvan Institute of Medical Research and Peter MacCallum Cancer Centre, 1 February 2018
WO/2018/018073, Methods of treating cancer, Ascend Biopharmaceuticals, 1 February 2018
WO/2018/017719, Methods for enhancing utrophin production via inhibition of microRNA, University of Pennsylvania and Murdoch University, 25 January 2018
WO/2018/014091, Insulin analogs, University of Utah, Walter and Eliza Hall Institute of Medical Research and La Trobe University, 25 January 2018
WO/2018/014078, Iridium complexes for cellular imaging, University of South Australia and Curtin University, 25 January 2018
WO/2018/014068, Attenuated Type I IFN CD47 combination therapy, Teva Pharmaceuticals Australia Pty Ltd, 25 January 2018
WO/2018/014067, Anti-CD47 combination therapy, Teva Pharmaceuticals Australia Pty Ltd, 25 January 2018
WO/2018/009972, Chimeric Antigen Receptor modified T cells, Peter MacCallum Cancer Institute, 18 January 2018
WO/2018/009547, Diagnosing COL6-related disorders and methods for treating same, The US Department of Health and Human Services with three scientists from Massachusetts General Hospital and Professor Steve Wilton of Murdoch University
WO/2018/004433, Nemertea-derived bioactive compounds, Five Swedish scientists including Johan Rosengren of the University of Queensland, 4 January 2018
WO/2018/000047, Method of treating immunoglobulin light chain amyloidosis, Prana Biotechnology, 4 January 2018
WO/2018/000028, Novel antibiotics, Boulos & Cooper Pharmaceuticals Pty Ltd, 4 January 2018
WO/2018/000013, Aesthetically elegant sexual lubricants and massage gels, Ansell, 4 January 2018
WO/2017/221158, Anti-parasitic compositions and methods, University of Canberra, 28 December 2017
WO/2017/220369, Antibodies against MAC-1, Baker IDI Heart and Diabetes Institute and Albert-Ludwigs-Universität Freiburg, 28 December 2017
WO/2017/219087, New thiosemicarbazone compounds and analogues thereof, University of Sydney, 28 December 2017
WO/2017/219086, Anti-ageing compounds, University of Sydney, 28 December 2017
WO/2017/219083, Activators of HIV latency, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, 28 December 2017
WO/2017/219081, Spider venom peptides and methods of use for modulating sodium channels, University of Queensland, 28 December 2017
WO/2017/219080, Treatment for myopia, University of Newcastle, 28 December 2017
WO/2017/219078, Allosteric regulation of haemostatic activity, University of Sydney, 28 December 2017
WO/2017/214683, Methods and compositions for the treatment or prophylaxis of an ectoparasitic infestation, Gretals Australia Pty Ltd, 21 December 2017
WO/2017/214681, Agents and methods for the diagnosis and treatment of diseases associated with extracellular matrix turnover, Baker IDI Heart and Diabetes Institute, 21 December 2017
WO/2017/214680, Adamantane compounds, University of Sydney, 21 December 2017
WO/2017/210749, Methods and products for treating autoimmune diseases, University of Adelaide, 14 December 2017
WO/2017/210735, Methods of treating neuroblastoma and reagents therefor, Garvan Institute of Medical Research and Peter MacCallum Cancer Institute, 14 December 2017
WO/2017/210726, Peptides for hair growth, Clinical Stem Cells Pty Ltd, 14 December 2017
WO/2017/205939, Vitamin D formulations and therapeutic uses thereof, Indigo Ridge Pty Ltd, 7 December 2017
WO/2017/205901, Hydrophilic polymer conjugate with multiple antiviral agents for treating a viral infection, Commonwealth Scientific and Industrial Research Organisation, 7 December 2017
WO/2017/205895, Skin care formulation, Embryogenesis Pty Ltd, 7 December 2017
WO/2017/203397, Inner ear plug, Cochlear Ltd, 30 November 2017
WO/2017/203368, Methods of treating autoimmune disease using allogeneic T cells, QIMR Berghofer Medical Research Institute, 30 November 2017
WO/2017/203362, Immune checkpoint inhibitors and cytotoxic T cells for the treatment of cancer, QIMR Berghofer Medical Research Institute, 30 November 2017
WO/2017/201585, Modulators of DUX4 for regulation of muscle function, Genea Biocells, 30 November 2017
WO/2017/201581, Non-toxic iron chelators with neuroprotective potential, University of Sydney, 30 November 2017
WO/2017/201579, Arthrogenic alphavirus vaccine, Griffith University, 30 November 2017
WO/2017/201573, A method of classification and treatment, Peter MacCallum Cancer Institute, 30 November 2017
WO/2017/201563, Treatment of alphavirus-induced inflammation, Griffith University, 30 November 2017
WO/2017/197463, Treatment of pain, Monash University and Queens University at Kingston (Canada), 23 November 2017
WO/2017/197453, Microencapsulated omega-3 polyunsaturated fatty acid glyceride compositions and processes for preparing the same, Deakin University, 23 November 2017
WO/2017/194912, Treatment of complement-mediated disorders, University of Cambridge (UK) and Sydney Children's Hospital Network, 16 November 2017
WO/2017/193169, Protection of plant extracts and compounds from degradation, Medlab Clinical Ltd, 16 November 2017
WO/2017/193161, Agent delivery system, WRS Therapeutics Pty Ltd, 16 November 2017
WO/2017/192699, Adeno-Associated Virus polynucleotides, polypeptides and virions, Children's Medical Research Institute, Sydney Children's Hospital Network and US Department of Health and Human Services, 9 November 2017
WO/2017/190197, Reagents for treatment of Hepatitis B Virus (HBV) infection and use thereof, Benitec Biopharma Ltd, 9 November 2017
WO/2017/190193, Method of prophylaxis of Zika virus infection, Starpharma Ltd, 9 November 2017
WO/2017/190183, Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith, T & A Pharma Pty Ltd, 9 November 2017
WO/2017/185142, Method for preventing and/or treating atrial fibrillation, University of Adelaide, 2 November 2017
WO/2017/185123, Veterinary composition, Alan Thompson, 2 November 2017
WO/2017/181245, Method of treating inflammation and promoting wound healing, Sang Pacific Enterprises Pty Ltd, 26 October 2017
WO/2017/181243, Method of treating or preventing liver conditions, CSL Ltd and B-Creative Sweden AB, 26 October 2017
WO/2017/181242, Chemotherapy improvements, Noxopharm, 26 October 2017
WO/2017/177283, Methods of manufacturing nutritional formulations, Clover Corporation Ltd, 19 October 2017
WO/2017/177277, Reagents for treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and use thereof, Benitec Biopharma Ltd, 19 October 2017
WO/2017/177270, Composition of proenzymes for cancer treatment, Propanc Biopharma, 19 October 2017
WO/2017/177265, Injectable composition for delivery of a biologically active agent, Capsular Technologies Pty Ltd, 19 October 2017
WO/2017/177262, Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier, University of Canberra, 19 October 2017
WO/2017/177261, Liposomal preparation and methods of treatment, Habi Pharma Pty Ltd, 19 October 2017
WO/2017/176403, Method and composition for dag mitigation on hair, Empire Technology Development LLC, 12 October 2017
WO/2017/173498, Isoflavonoid composition with improved pharmacokinetics, Noxopharm, 12 October 2017
WO/2017/173497, Targeted drug delivery, Noxopharm, 12 October 2017
WO/2017/173496, Radiotherapy improvements, Noxopharm, 12 October 2017
WO/2017/173494, Method of treating atherosclerosis, CSL Ltd, 12 October 2017
WO/2017/173487, Nanofibrous mat containing ceramic particles with releasable dopant, SG Ventures Pty Ltd and Nanopharma a.s. (Czechia)
WO/2017/173478, Acoustic wave mediated non-invasive drug delivery, Mupharma Pty Ltd, 12 October 2017
WO/2017/173474, Improvements in cancer treatment, Noxopharm, 12 October 2017
WO/2017/165908, Method of inhibiting high fat diet-related conditions, South Australian Health and Medical Research Institute and Ocean University of China (China), 5 October 2017
WO/2017/161414, Administration of an anti- LGR5 monoclonal antibody, Bionomics Ltd, 28 September 2017
WO/2017/161408, Dental adhesive compositions, SDI Ltd, 28 September 2017
WO/2017/161402, Formulation and method for the prevention and/or treatment of hangover symptoms, Phoenix Pharmaceuticals Australia Pty Ltd, 28 September 2017
WO/2017/160587, Neutralizing monoclonal antibodies to Il-25 and uses thereof, Abeome Corporation (US) with Nathan Bartlett and others
WO/2017/156591, Osteoarthritis miRNAs, Murdoch Childrens Research Institute and University of Sydney, 21 September 2017
WO/2017/156580, Colony forming medium and use thereof, Cynata Therapeutics, 21 September 2017
WO/2017/153521, Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
WO/2017/153520, Benzopiperidine derivatives and their use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 4 September 2017
WO/2017/153519, 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
017/153519, 3-oxa-8-azabicyclo[3.2.1]octane derivatives and thier use in the treatment of cancer and hemoglobinopathies, CTxT Pty Ltd, 14 September 2017
WO/2017/153518, PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/153515, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/153513, Tetrahydroisoquinolines as PRMT5 inhibitors, CTxT Pty Ltd, 14 September 2017
WO/2017/152237, Novel analogues of Desferrioxamine B (DFOB), University of Sydney, 14 September 2017
WO/2017/147654, Use of phosphorylated tau and p38gamma to treat a neurological condition, University of New South Wales, 8 September 2017
WO/2017/147653, Methods of treating bone diseases, disorders and/or injuries and reagents therefor, Cellmid Ltd, 8 September 2017
WO/2017/147649, Methods of treatment, Magellan Stem Cells Pty Ltd, 8 September 2017
WO/2017/143406, Multi-specific molecules, Imunexus Pty Ltd, 31 August 2017
WO/2017/143397, Inhibitors of β-arrestin-neurokinin 1 receptor interactions for the treatment of pain, Monash University, 31 August 2017
WO/2017/142825, N3-substituted iminopyrimidinones as antimalarial agents, Merck & Co. (US) with Walter and Eliza Hall Institute of Medical Research, 24 August 2017
WO/2017/142821, Compounds for the treatment of malaria, Merck & Co. (US) with Walter and Eliza Hall Institute of Medical Research, 24 August 2017
WO/2017/139854, Compositions and methods for the treatment of sinus disease and disorders, ENT Technologies Pty Ltd, 24 August 2017
WO/2017/139849, Anti-virus agent and method for treatment of viral infection, Recce Ltd, 24 August 2017
WO/2017/139846, Formulation and method of use, ATP Institute Pty Ltd, 24 August 2017
WO/2017/139845, Novel alpha conotoxin peptides, University of Queensland, 24 August 2017
WO/2017/139290, Tralokinumab delivery device, Medimmune (US) and Unilife, 17 August 2017
WO/2017/136871, Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
WO/2017/136870, Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof, Pharmaxis Ltd, 17 August 2017
WO/2017/132728, Proteinaceous compounds and uses therefor, University of Canberra, 10 August 2017
WO/2017/127892, Cancer treatment, Propanc Biopharma, 3 August 2017
WO/2017/124156, Compositions that brighten skin, provide sun protection, and permit Vitamin D production, Ernest Armstong, 27 July 2017
WO/2017/124147, Novel biomolecule conjugates and uses therefor, University of Western Australia and Sanford Burnham Prebys Medical Discovery Institute (US), 27 July 2017
WO/2017/117631, Mutated truncated von Willebrand factor, CSL Ltd, 13 July 2017
WO/2017/117630, Mutated von Willebrand factor, CSL Ltd, 13 July 2017
WO/2017/117627, Drug release device and use, Jurox Pty Ltd, 13 July 2017
WO/2017/112792, Tripartite modulators of endosomal G Protein-Coupled Receptors, Takeda Pharmaceutical Company (Japan) with two Monash University scientists, among others, 29 June 2017
WO/2017/106930, Compounds, Commonwealth Scientific and Industrial Research Organisation, 29 June 2017
WO/2017/106926, Nucleic acid oligomers and uses therefor, Queensland University of Technology, 29 June 2017
WO/2017/106899, Therapeutic methods using erythrocytes, Sangui Bio Pty Ltd, 29 June 2017
WO/2017/100863, Injectable composition and a method of treatment of the physical addiction, Verita Research Pte Ltd, 22 June 2017
WO/2017/100861, Inhibition of cytokine-induced SH2 protein in NK cells, Walter and Eliza Hall Institute of Medical Research, 22 June 2017
WO/2017/100860, Exfoliant bar, DPP Pharmaceuticals Pty Ltd, 22 June 2017
WO/2017/100858, Polymer composite for controlled release of an agent, Commonwealth Scientific and Industrial Research Organisation, 22 June 2017
WO/2017/100849, 6-oxopurine phosphoribosyl transferase inhibitors, University of Queensland and Institute of Organic Chemistry and Biochemistry (Czechia), 22 June 2017
WO/2017/100825, A pharmaceutical composition and uses therefor, Robert Gilligan and Wayne Daley, 22 June 2017
WO/2017/100819, Modular syntheses of discoipyrrole type alkaloids and analogues, Australian National University, 22 June 2017

New Zealand applications

Here are the 17 PCT patent applications relevant to New Zealand's Life Sciences sector that have published since 22 June 2017, for a publication rate of 0.4 applications per week:

WO/2018/063008, Beta-caseins and gut microbiota, A2 Milk Company, 5 April 2018
WO/2018/038623, Improvements in parasite treatments, Donaghys, 1 March 2018
WO/2018/035706, Traditional Chinese medicine preparation for atopic dermatitis, preparation method therefor and use thereof, Jian Tan, 1 March 2018
WO/2018/020473, Dairy product and process, Fonterra Co-Operative Group and five inventors including Bing Wang of Charles Sturt University, 1 February 2018
WO/2017/217868, Water-dispersible propolis composition, Andrew Lavrent, 21 December 2017
WO/2017/213524, Treatment of neurodegenerative disorders, Garth Cooper, 14 December 2017
WO/2017/200396, Antibacterial compositions, David Ackerley and Janine Copp, 23 November 2017
WO/2017/200391, Compositions comprising L-Theanine, proanthocyanidin/s and a catechin and uses thereof, Alphagen NZ, 23 November 2017
WO/2017/192620, Novel peptides and peptidomimetics, University of Auckland and Ocunexus Therapeutics, 9 November 2017
WO/2017/183996, Combination,therapeutic uses and prophylactic uses, Quantec Ltd, 26 October 2017
WO/2017/179996, Collagen-based device having antifungal properties, Aroa Biosurgery, 19 October 2017
WO/2017/171563, Beta-caseins and cognitive function, A2 Milk Company, 5 October 2017
WO/2017/164750, Therapeutic compositions and uses thereof, Manuka Health New Zealand Ltd, 28 September 2017
WO/2017/153943, Topical composition, Biopharm NZ Ltd, 14 September 2017
WO/2017/142424, Treatment of neurodegenerative disorders, Garth Cooper, 24 August 2017
WO/2017/131534, Treatment of vascular anomalies, Gillies McIndoe Research Institute, 3 August 2017
WO/2017/111618, Infant formula comprising human milk peptides, A2 Milk Company Ltd, 29 June 2017